### **Briefings for Michal**

- PRIA/registration overview 2/23<sup>rd</sup> (complete)
- Dicamba 2/18<sup>th</sup> (complete)
- Sulfoxaflor 3/4<sup>th</sup> (complete)
- Pet incidents 3/31<sup>st</sup> (complete)
- FDA/EPA jurisdiction 4/12<sup>th</sup> (complete)
- SW2 revocation options 5/3<sup>rd</sup> (complete)
- Antibiotics 5/17<sup>th</sup>

-

### New Active Ingredients (include original PRIA date)

- Tetraniliprole completed!
- Broflanilide completed!
- Picarbutrazox completed!
- Fluxametamide completed!
- Fluindapyr PD signed. PRIA Date 3/5/21 (Original PRIA date 5/29/20) (FB) FD with OPP-IO for review
- Trifludimoxazin PD signed. PRIA date 4/21/21 (Original PRIA date 10/16/2020) (FHB) FD with OPP-IO for review
- L-Glufosinate Ammonium Risk Assessment phase. PRIA date 10/12/2021. ESA issue. Any feedback?

### **Other Chemical Actions**

Ex. 5 Deliberative Process (DP)

## Ex. 5 Deliberative Process (DP)

### Other Actions - AA-Level/OD/High Visibility Items

- FDA/EPA jurisdiction follow up briefing for Ed 3/10<sup>th</sup> RD sent an email for Soloman; anything else needed?
- COVID-19 Activities Sect 18s –

Ex. 5 Deliberative Process (DP)

- **OIG Audits**

Draft ( Ex. 5 Deliberative Process (DP)

**PFAS** – RD working with Clark on submissions

### Ex. 5 Deliberative Process (DP)

- Inerts meeting with CLA waiting on additional information from CLA
- FLS/FLAG: debuted Performance Management Toolkit for Federal Supervisors last week; interest from other AA/Regional FLAG reps in sharing it with their supervisors
- 24c for cannabis J. Housenger letter; OPP position?

### Business/process/technology

- ISB FEP/21-day backlog:
  - backlog addressed by end of April; RD SWAT team addressing newer receipts
  - Michal feedback on expediting all covid actions? Any updates?
- eCSF/OPPEL OPP priority? ITRMD report May soft launch; requesting time at an OPP staff meeting

### **Speaking Engagements –**

#### People/Personnel/Resources

Ex. 6 Personal Privacy (PP)

ED\_006319\_00000411-00002

# Ex. 6 Personal Privacy (PP)

CA topics (Karen Morrison):

Ex. 5 Deliberative Process (DP)